Your browser doesn't support javascript.
loading
pVHL suppresses kinase activity of Akt in a proline-hydroxylation-dependent manner.
Guo, Jianping; Chakraborty, Abhishek A; Liu, Pengda; Gan, Wenjian; Zheng, Xingnan; Inuzuka, Hiroyuki; Wang, Bin; Zhang, Jinfang; Zhang, Linli; Yuan, Min; Novak, Jesse; Cheng, Jin Q; Toker, Alex; Signoretti, Sabina; Zhang, Qing; Asara, John M; Kaelin, William G; Wei, Wenyi.
Afiliação
  • Guo J; Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
  • Chakraborty AA; Department of Medicine, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
  • Liu P; Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
  • Gan W; Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
  • Zheng X; Department of Pathology and Laboratory Medicine, Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine, Chapel Hill, NC 27599, USA.
  • Inuzuka H; Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
  • Wang B; Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
  • Zhang J; Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
  • Zhang L; Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
  • Yuan M; Division of Signal Transduction, Beth Israel Deaconess Medical Center and Department of Medicine, Harvard Medical School, Boston, MA 02115, USA.
  • Novak J; Department of Pathology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
  • Cheng JQ; Department of Molecular Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA.
  • Toker A; Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
  • Signoretti S; Department of Pathology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
  • Zhang Q; Department of Pathology and Laboratory Medicine, Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine, Chapel Hill, NC 27599, USA.
  • Asara JM; Division of Signal Transduction, Beth Israel Deaconess Medical Center and Department of Medicine, Harvard Medical School, Boston, MA 02115, USA.
  • Kaelin WG; Department of Medicine, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA. Howard Hughes Medical Institute, Chevy Chase, MD 20815, USA.
  • Wei W; Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA. wwei2@bidmc.harvard.edu.
Science ; 353(6302): 929-32, 2016 08 26.
Article em En | MEDLINE | ID: mdl-27563096
ABSTRACT
Activation of the serine-threonine kinase Akt promotes the survival and proliferation of various cancers. Hypoxia promotes the resistance of tumor cells to specific therapies. We therefore explored a possible link between hypoxia and Akt activity. We found that Akt was prolyl-hydroxylated by the oxygen-dependent hydroxylase EglN1. The von Hippel-Lindau protein (pVHL) bound directly to hydroxylated Akt and inhibited Akt activity. In cells lacking oxygen or functional pVHL, Akt was activated to promote cell survival and tumorigenesis. We also identified cancer-associated Akt mutations that impair Akt hydroxylation and subsequent recognition by pVHL, thus leading to Akt hyperactivation. Our results show that microenvironmental changes, such as hypoxia, can affect tumor behaviors by altering Akt activation, which has a critical role in tumor growth and therapeutic resistance.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Prolina / Proteína Supressora de Tumor Von Hippel-Lindau / Proteínas Proto-Oncogênicas c-akt / Hipóxia Tumoral / Neoplasias Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Science Ano de publicação: 2016 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Prolina / Proteína Supressora de Tumor Von Hippel-Lindau / Proteínas Proto-Oncogênicas c-akt / Hipóxia Tumoral / Neoplasias Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Science Ano de publicação: 2016 Tipo de documento: Article País de afiliação: Estados Unidos